TY - JOUR
T1 - Cost-utility analysis on robot-assisted and laparoscopic prostatectomy based on long-term functional outcomes
AU - Lindenberg, Melanie A.
AU - Retèl, Valesca P.
AU - van der Poel, Henk G.
AU - Bandstra, Ferdau
AU - Wijburg, Carl
AU - van Harten, Wim H.
N1 - Funding Information:
M.L. conceptualized the research and manuscript together with W.v.H., V.R. and H.v.d.P. H.v.d.P., M.L., W.v.H. and V.R. had discussions regarding the methodology. The analysis was performed by M.L. and was supervised by W.v.H., V.R. and H.v.d.P. Data was collected and curated by M.L. The manuscript was written by M.L. under supervision of W.v.H., V.R. and H.v.d.P. The manuscript was reviewed and edited by all authors (W.v.H., V.R., H.v.d.P., F.B., C.W.). Funding for the research was acquired by efforts from M.L., V.R. and W.v.H.
Funding Information:
W.H. van Harten received funding from Intuitive surgical to continue and finish this study. The sponsor had no influence on the design of the study, the methodologies used and the results presented.
Publisher Copyright:
© 2022, The Author(s).
Financial transaction number:
342215512
PY - 2022/12
Y1 - 2022/12
N2 - Robot-Assisted Radical Prostatectomy (RARP) is one of the standard treatment options for prostate cancer. However, controversy still exists on its added value. Based on a recent large-sample retrospective cluster study from the Netherlands showing significantly improved long-term urinary functioning after RARP compared to Laparoscopic RP (LRP), we evaluated the cost-effectiveness of RARP compared to LRP. A decision tree was constructed to measure the costs and effects from a Dutch societal perspective over a ~ 7 year time-horizon. The input was based on the aforementioned study, including patient-reported consumption of addition care and consumed care for ergonomic issues reported by surgeons. Intervention costs were calculated using a bottom-up costing analysis in 5 hospitals. Finally, a probabilistic-, one-way sensitivity- and scenario analyses were performed to show possible decision uncertainty. The intervention costs were €9964 for RARP and €7253 for LRP. Total trajectory costs were €12,078 for RARP and €10,049 for LRP. RARP showed higher QALYs compared to LRP (6.17 vs 6.11). The incremental cost-utility ratio (ICUR) was €34,206 per QALY gained, in favour of RARP. As a best-case scenario, when RARP is being centralized (> 150 cases/year), total trajectory costs decreased to €10,377 having a higher utilization, and a shorter procedure time and length of stay resulting in an ICUR of €3495 per QALY gained. RARP showed to be cost-effective compared to LRP based on data from a population-based, large scale study with 7 years of follow-up. This is a clear incentive to fully reimburse RARP, especially when hospitals provide RARP centralized.
AB - Robot-Assisted Radical Prostatectomy (RARP) is one of the standard treatment options for prostate cancer. However, controversy still exists on its added value. Based on a recent large-sample retrospective cluster study from the Netherlands showing significantly improved long-term urinary functioning after RARP compared to Laparoscopic RP (LRP), we evaluated the cost-effectiveness of RARP compared to LRP. A decision tree was constructed to measure the costs and effects from a Dutch societal perspective over a ~ 7 year time-horizon. The input was based on the aforementioned study, including patient-reported consumption of addition care and consumed care for ergonomic issues reported by surgeons. Intervention costs were calculated using a bottom-up costing analysis in 5 hospitals. Finally, a probabilistic-, one-way sensitivity- and scenario analyses were performed to show possible decision uncertainty. The intervention costs were €9964 for RARP and €7253 for LRP. Total trajectory costs were €12,078 for RARP and €10,049 for LRP. RARP showed higher QALYs compared to LRP (6.17 vs 6.11). The incremental cost-utility ratio (ICUR) was €34,206 per QALY gained, in favour of RARP. As a best-case scenario, when RARP is being centralized (> 150 cases/year), total trajectory costs decreased to €10,377 having a higher utilization, and a shorter procedure time and length of stay resulting in an ICUR of €3495 per QALY gained. RARP showed to be cost-effective compared to LRP based on data from a population-based, large scale study with 7 years of follow-up. This is a clear incentive to fully reimburse RARP, especially when hospitals provide RARP centralized.
UR - http://www.scopus.com/inward/record.url?scp=85129876177&partnerID=8YFLogxK
U2 - 10.1038/s41598-022-10746-3
DO - 10.1038/s41598-022-10746-3
M3 - Article
C2 - 35538174
AN - SCOPUS:85129876177
SN - 2045-2322
VL - 12
JO - Scientific reports
JF - Scientific reports
IS - 1
M1 - 7658
ER -
